A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy

Annals of Oncology

Volumn 23, Issue 4, 2012, Pages 860-866

  Stebbing, J ^a   Sharma, A ^a   North, B ^a   Athersuch, T J ^a   Zebrowski, A ^a   Pchejetski, D ^a   Coombes, R C ^a   Nicholson, J K ^a   Keun, H C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarkers; Breast cancer; Diabetes; Metabolic syndrome; Metabolomics

Indexed keywords

ALANINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GLUCOSE; LACTIC ACID; LIPID; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LACTATE BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; METABOLITE; METABOLOMICS; METASTASIS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHENOTYPIC VARIATION; PREDICTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TREATMENT DURATION; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 84859509386     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr347     Document Type: Article

References (49)

1. Day C. Metabolic syndrome, or what you will: definitions and epidemiology. Diab Vasc Dis Res 2007; 4: 32-38.
2. Grundy SM, Brewer HB Jr, Cleeman JI et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
3. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002; 3: 565-574.
4. Xue F, Michels KB. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 2007; 86: s823-s835.
5. Yancik R, Wesley MN, Ries LA et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001; 285: 885-892.
6. Stoll BA. Oestrogen/insulin-like growth factor-I receptor interaction in early breast cancer: clinical implications. Ann Oncol 2002; 13: 191-196.
7. Sinicrope FA, Dannenberg AJ. Obesity and breast cancer prognosis: weight of the evidence. J Clin Oncol 2011; 29: 4-7.
8. DeCensi A, Gennari A. Insulin breast cancer connection: confirmatory data set the stage for better care. J Clin Oncol 2011; 29: 7-10.
9. Jiralerspong S, Palla SL, Giordano SH et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27: 3297-3302.
10. Chlebowski RT, Blackburn GL, Thomson CA et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 2006; 98: 1767-1776.
11. Pierce JP, Stefanick ML, Flatt SW et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol 2007; 25: 2345-2351.
12. Keun HC, Sidhu J, Pchejetski D et al. Serum molecular signatures of weight change during early breast cancer chemotherapy. Clin Cancer Res 2009; 15: 6716-6723.
13. Beckonert O, Keun HC, Ebbels TM et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2007; 2: 2692-2703.
14. Fossel ET, Carr JM, McDonagh J. Detection of malignant tumors. Watersuppressed proton nuclear magnetic resonance spectroscopy of plasma. N Engl J Med 1986; 315: 1369-1376.
15. Odunsi K, Wollman RM, Ambrosone CB et al. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer 2005; 113: 782-788.
16. Tiziani S, Lopes V, Gunther UL. Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia 2009; 11: 269-276, 264p following 269.
17. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
18. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
19. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
20. Pearce JT, Athersuch TJ, Ebbels TM et al. Robust algorithms for automated chemical shift calibration of 1D 1H NMR spectra of blood serum. Anal Chem 2008; 80: 7158-7162.
21. Harrell FE. Regression Modelling Strategies. R Package Version 2.1-0. http://CRAN.R-project.org/package=rms.2009 (20 July 2011, date last accessed).
22. Somers R. A new asymmetric measure for ordinal variables. Am Sociol Rev 1962; 27: 799-811.
23. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006; 25: 127-141.
24. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics 1955; 11: 375-386.
25. Mallett S, Royston P, Dutton S et al. Reporting methods in studies developing prognostic models in cancer: a review. BMC Med 2010; 8: 20.
26. Van Belle G. Statistical Rules of Thumb. Hoboken, NJ: John Wiley & Sons, Inc. 2008; 125-126.
27. Tuthill M, Pell R, Guiliani R et al. Peritoneal disease in breast cancer: a specific entity with an extremely poor prognosis. Eur J Cancer 2009; 45: 2146-2149.
28. Lee B, Franklin I, Lewis JS et al. The efficacy of percutaneous vertebroplasty for vertebral metastases associated with solid malignancies. Eur J Cancer 2009; 45: 1597-1602.
29. van den Brandt PA, Spiegelman D, Yaun SS et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000; 152: 514-527.
30. Renehan AG. Bariatric surgery, weight reduction, and cancer prevention. Lancet Oncol 2009; 10: 640-641.
31. Healy LA, Ryan AM, Carroll P et al. Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol) 2010; 22: 281-288.
32. Vigneri P, Frasca F, Sciacca L et al. Diabetes and cancer. Endocr Relat Cancer 2009; 16: 1103-1123.
33. Muti P, Quattrin T, Grant BJ et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2002; 11: 1361-1368.
34. Nyholm H, Djursing H, Hagen C et al. Androgens and estrogens in postmenopausal insulin-treated diabetic women. J Clin Endocrinol Metab 1989; 69: 946-949.
35. McTernan PG, Anwar A, Eggo MC et al. Gender differences in the regulation of P450 aromatase expression and activity in human adipose tissue. Int J Obes Relat Metab Disord 2000; 24: 875-881.
36. Michels KB, Solomon CG, Hu FB et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 2003; 26: 1752-1758.
37. Gunter MJ, Hoover DR, Yu H et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009; 101: 48-60.
38. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002; 51: 2944-2950.
39. Crawford SO, Ambrose MS, Hoogeveen RC et al. Association of lactate with blood pressure before and after rapid weight loss. Am J Hypertens 2008; 21: 1337-1342.
40. Liu C, Wu J, Zhu J et al. Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81. J Biol Chem 2009; 284: 2811-2822.
41. Gatenby RA, Gawlinski ET, Gmitro AF et al. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 2006; 66: 5216-5223.
42. Fischer K, Hoffmann P, Voelkl S et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007; 109: 3812-3819.
43. Murray CM, Hutchinson R, Bantick JR et al. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nat Chem Biol 2005; 1: 371-376.
44. Sonveaux P, Vegran F, Schroeder T et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008; 118: 3930-3942.
45. Nicholson JK, O'Flynn MP, Sadler PJ et al. Proton-nuclear-magnetic-resonance studies of serum, plasma and urine from fasting normal and diabetic subjects. Biochem J 1984; 217: 365-375.
46. Leij-Halfwerk S, Dagnelie PC, van Den Berg JW et al. Weight loss and elevated gluconeogenesis from alanine in lung cancer patients. Am J Clin Nutr 2000; 71: 583-589.
47. Yun J, Rago C, Cheong I et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009; 325: 1555-1559.
48. Cusi K, DeFronzo R. Metformin: a review of its metabolic effects. Diabetes Rev 1998; 6: 89-131.
49. Flanagan J, Gray PK, Hahn N et al. Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol 2011; 22: 801-807.